Featured Press Releases

Pilatus Biosciences Inc. earns FDA Orphan Drug Designation for PLT012, targeting liver and intrahepatic bile duct cancer

Pilatus Biosciences Inc. earns FDA Orphan Drug Designation for PLT012, targeting liver and intrahepatic bile duct cancer

BioCare collaborates with AeroSafe Global to introduce sustainable cold chain solutions

BioCare collaborates with AeroSafe Global to introduce sustainable cold chain solutions

  • 02 Oct 2024

BioCare, a leader in specialty pharmaceutical distribution, is excited to announce its new...

Long Island University alumnus Dr. Howard Murad

Long Island University alumnus Dr. Howard Murad '62 launches the Inclusive Wellness Initiative with the Arnold & Marie Schwartz College of Pharmacy and Health Sciences

ProductLife Group Appoints Dr. James Burt as CEO

ProductLife Group Appoints Dr. James Burt as CEO

Hologic to Present New Data Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions

Hologic to Present New Data Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions

IMAAVY® (nipocalimab-aahu) demonstrated rapid onset and durable hemoglobin response in a pivotal Phase 2/3 study of warm autoimmune hemolytic anemia (wAIHA), a disease with no FDA-approved therapies

IMAAVY® (nipocalimab-aahu) demonstrated rapid onset and durable hemoglobin response in a pivotal Phase 2/3 study of warm autoimmune hemolytic anemia (wAIHA), a disease with no FDA-approved therapies

Why the Pharmacy System Rewards the Wrong Results: It Is Working as Designed

Why the Pharmacy System Rewards the Wrong Results: It Is Working as Designed

  • SHARx
  • 04 Aug 2026
Triquetra Health Launched BioActive Vitamin B1™—the First Complete B1 Activation System with a 600 mg Research-Matched Dose and Full Cofactor Support

Triquetra Health Launched BioActive Vitamin B1™—the First Complete B1 Activation System with a 600 mg Research-Matched Dose and Full Cofactor Support

  • Triquetra Health LLC
  • 03 Aug 2026
Dallas-Based Microbiome Brand resbiotic® Comes Home to Texas with Launch at H-E-B

Dallas-Based Microbiome Brand resbiotic® Comes Home to Texas with Launch at H-E-B

  • Resbiotic Nutrition, Inc.
  • 03 Aug 2026
US Capital Global Securities Announces $20 Million Offering for Thplasma to Invest in the Future of Plasma Therapeutics

US Capital Global Securities Announces $20 Million Offering for Thplasma to Invest in the Future of Plasma Therapeutics

  • US Capital Global
  • 03 Aug 2026
Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection in two single-dose vial strengths

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection in two single-dose vial strengths

  • Glenmark Pharmaceuticals
  • 30 Jul 2026
EMS and BD expand access to GLP-1 therapies in Brazil by launching semaglutide.

EMS and BD expand access to GLP-1 therapies in Brazil by launching semaglutide.

  • BD (Becton, Dickinson and Company)
  • 29 Jul 2026
The Digital Pharma Advances Conference 2026

Most Popular
August   2026
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31            

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.